Exanthema Market Report and Forecast 2025-2034
Description
The exanthema market size was valued at USD 1390.27 Million in 2024, driven by the increasing incidence of viral and bacterial infections and innovations in diagnostic methods across the 8 major markets. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to achieve a value of USD 2513.35 Million by 2034.
Exanthema Market Overview
Exanthema is commonly triggered by infections, often viral, and can manifest as a response to toxins from the organism, skin damage, or an immune reaction. These rashes, nonspecific in nature, show as spots or blotches that may or may not cause itching. They typically spread widely across the body, often more prominently on the trunk than the limbs. Before the rash appears, patients might experience a range of general symptoms including fever, malaise, headaches, reduced appetite, abdominal pain, irritability, muscle aches, and pains.
The exanthema market growth is driven by the rising incidence of viral and bacterial infections, causing skin rashes and related diseases. The escalating prevalence of infectious diseases like measles, rubella, and chickenpox, is significantly contributing to increased exanthema cases, which is expected to require enhanced attention to provide preventive measures and vaccinations, further propelling the market growth. The market is further driven by improvements in healthcare facilities and infrastructure to provide better diagnosis, treatment, and management of exanthemas, encouraging more people to seek medical care.
Consequently, the market is also witnessing innovations in diagnostic methods such as molecular testing and serological assays, acting as major drivers to further bolster the exanthema market demand. Governments and healthcare organizations are launching interesting initiatives to promote vaccination campaigns, especially for diseases linked to exanthemas are contributing to increased market demand.
Initiatives Aiding the Market Growth
The market demand is anticipated to experience significant growth due to a combination of factors such as national and international organizations acting and launching initiatives toward the prevention of exanthema in regions. For instance, the IA2030 Measles & Rubella Partnership, a collaborative initiative led by multiple prominent entities in the field of healthcare and immunization including the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, UNICEF, and the World Health Organization (WHO). Such initiatives are aligned towards a common goal of spreading awareness regarding exanthema, likely to contribute significantly to the rising exanthema market share.
Surge in Supplies Due to Unforeseen Outbreak
The market is witnessing a surge in demand for increased treatment supplies and drugs due to the emergence of the condition in some regions. For instance, a recent surge in measles cases in Romania including 460 confirmed cases by August 2023 and significant outbreaks in several counties, has escalated the urgency for effective interventions and preventive measures, elevating the demand for relevant treatments and vaccinations. The market growth is expected to witness escalation owing to the sudden surge in the demand for treatment and vaccination in affecting regions.
FDA Approvals to Aid the Market Growth
The exanthema market growth is also driven by new FDA approvals creating a wave of hope for healthcare professionals and patients. For instance, Merck's groundbreaking announcement of the FDA's approval for intramuscular administration of the MMRV family vaccines—M-M-R®II, VARIVAX®, and ProQuad® marks have also collectively marked a pivotal advancement. This alteration from the conventional subcutaneous injection to intramuscular administration broadens the vaccination landscape enhancing convenience and accessibility as well. Such developments signify promising increased demand for the exanthem market in the forecast period.
Exanthema Market Segmentations
“Exanthema Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Considering the geographical landscape, the United States is leading the regional market. The market is expected to dominate in the forecast period due to factors such as the presence of the largest patient pool for exanthema and also representing the largest market for its treatment.
The latest data by the CDC Centers for Disease Control and Prevention has revealed that more than 3,700 babies were born with syphilis in 2022, which was more than 10 times the number in 2012. The increase in newborn syphilis follows rising syphilis cases among women of reproductive age combined with social and economic factors that create barriers to high-quality prenatal care and ongoing declines in the prevention infrastructure and resources.
The United States has seen a rise in cases of syphilis and congenital syphilis, leading senior leadership at the U.S. Department of Health and Human Services (HHS) to establish the National Syphilis and Congenital Syphilis Syndemic Federal Taskforce. This task force is dedicated to leading a national public health response to address the issue.
Exanthema Market: Competitor Landscape
In February 2023, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Exanthema Market Overview
Exanthema is commonly triggered by infections, often viral, and can manifest as a response to toxins from the organism, skin damage, or an immune reaction. These rashes, nonspecific in nature, show as spots or blotches that may or may not cause itching. They typically spread widely across the body, often more prominently on the trunk than the limbs. Before the rash appears, patients might experience a range of general symptoms including fever, malaise, headaches, reduced appetite, abdominal pain, irritability, muscle aches, and pains.
The exanthema market growth is driven by the rising incidence of viral and bacterial infections, causing skin rashes and related diseases. The escalating prevalence of infectious diseases like measles, rubella, and chickenpox, is significantly contributing to increased exanthema cases, which is expected to require enhanced attention to provide preventive measures and vaccinations, further propelling the market growth. The market is further driven by improvements in healthcare facilities and infrastructure to provide better diagnosis, treatment, and management of exanthemas, encouraging more people to seek medical care.
Consequently, the market is also witnessing innovations in diagnostic methods such as molecular testing and serological assays, acting as major drivers to further bolster the exanthema market demand. Governments and healthcare organizations are launching interesting initiatives to promote vaccination campaigns, especially for diseases linked to exanthemas are contributing to increased market demand.
Initiatives Aiding the Market Growth
The market demand is anticipated to experience significant growth due to a combination of factors such as national and international organizations acting and launching initiatives toward the prevention of exanthema in regions. For instance, the IA2030 Measles & Rubella Partnership, a collaborative initiative led by multiple prominent entities in the field of healthcare and immunization including the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, UNICEF, and the World Health Organization (WHO). Such initiatives are aligned towards a common goal of spreading awareness regarding exanthema, likely to contribute significantly to the rising exanthema market share.
Surge in Supplies Due to Unforeseen Outbreak
The market is witnessing a surge in demand for increased treatment supplies and drugs due to the emergence of the condition in some regions. For instance, a recent surge in measles cases in Romania including 460 confirmed cases by August 2023 and significant outbreaks in several counties, has escalated the urgency for effective interventions and preventive measures, elevating the demand for relevant treatments and vaccinations. The market growth is expected to witness escalation owing to the sudden surge in the demand for treatment and vaccination in affecting regions.
FDA Approvals to Aid the Market Growth
The exanthema market growth is also driven by new FDA approvals creating a wave of hope for healthcare professionals and patients. For instance, Merck's groundbreaking announcement of the FDA's approval for intramuscular administration of the MMRV family vaccines—M-M-R®II, VARIVAX®, and ProQuad® marks have also collectively marked a pivotal advancement. This alteration from the conventional subcutaneous injection to intramuscular administration broadens the vaccination landscape enhancing convenience and accessibility as well. Such developments signify promising increased demand for the exanthem market in the forecast period.
Exanthema Market Segmentations
“Exanthema Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Bacterial
- Viral
- Others
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Anti-Pyretic
- Emollients
- Liquids
- Others
- Corticosteroids
- Antiseizure Agents
- Others
- Oral
- Parenteral
- Others
- Hospital Pharmacy
- Retail Pharmacy
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- China
Considering the geographical landscape, the United States is leading the regional market. The market is expected to dominate in the forecast period due to factors such as the presence of the largest patient pool for exanthema and also representing the largest market for its treatment.
The latest data by the CDC Centers for Disease Control and Prevention has revealed that more than 3,700 babies were born with syphilis in 2022, which was more than 10 times the number in 2012. The increase in newborn syphilis follows rising syphilis cases among women of reproductive age combined with social and economic factors that create barriers to high-quality prenatal care and ongoing declines in the prevention infrastructure and resources.
The United States has seen a rise in cases of syphilis and congenital syphilis, leading senior leadership at the U.S. Department of Health and Human Services (HHS) to establish the National Syphilis and Congenital Syphilis Syndemic Federal Taskforce. This task force is dedicated to leading a national public health response to address the issue.
Exanthema Market: Competitor Landscape
In February 2023, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries
- Bristol Myers Squibb Company
- Bayer AG
- Sun Pharmaceutical Industries
- Manus Aktteva Biopharma LLP
- Perrigo Company plc
- Novartis AG
- GSK Plc.
- CIRON Drugs & Pharmaceuticals Pvt. Ltd.
- Concord Laboratories
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Exanthema Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Exanthema Epidemiology Analysis – 8 Major Markets
- 5.1 8MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Exanthema Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Exanthema Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Exanthema Epidemiology Forecast (2018-2034)
- 5.3.2 France Exanthema Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Exanthema Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Exanthema Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Exanthema Epidemiology Forecast (2018-2034)
- 5.4 Japan Exanthema Epidemiology Forecast (2018-2034)
- 5.5 China Exanthema Epidemiology Forecast (2018-2034)
- 6 Exanthema Market Overview – 8 Major Markets
- 6.1 Exanthema Market Historical Value (2018-2024)
- 6.2 Exanthema Market Forecast Value (2025-2034)
- 7 Exanthema Market Landscape – 8 Major Markets
- 7.1 Exanthema Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Exanthema Product Landscape
- 7.2.1 Analysis by Disease Type
- 7.2.2 Analysis by Therapy Type
- 7.2.3 Analysis by Treatment
- 7.2.4 Analysis by Drugs
- 7.2.5 Analysis by Route of Administration
- 7.2.6 Analysis by Distribution Channel
- 8 Exanthema Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Exanthema Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.2.1 Strengths
- 10.2.2 Weaknesses
- 10.2.3 Opportunities
- 10.2.4 Threats
- 10.3 Porter’s Five Forces Model
- 10.3.1 Bargaining Power of Suppliers
- 10.3.2 Bargaining Power of Buyers
- 10.3.3 Threat of New Entrants
- 10.3.4 Threat of Substitutes
- 10.3.5 Degree of Rivalry
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Exanthema Market Segmentation – 8 Major Markets
- 11.1 Exanthema Market by Disease Type
- 11.1.1 Market Overview
- 11.1.2 Bacterial
- 11.1.3 Viral
- 11.1.4 Others
- 11.2 Exanthema Market by Therapy Type
- 11.2.1 Market Overview
- 11.2.2 Chemotherapy
- 11.2.3 Radiation Therapy
- 11.2.4 Targeted Therapy
- 11.3 Exanthema Market by Treatment
- 11.3.1 Market Overview
- 11.3.2 Anti-Pyretic
- 11.3.3 Emollients
- 11.3.4 Liquids
- 11.3.5 Others
- 11.4 Exanthema Market by Drugs
- 11.4.1 Market Overview
- 11.4.2 Corticosteroids
- 11.4.3 Antiseizure Agents
- 11.4.4 Others
- 11.5 Exanthema Market by Route of Administration
- 11.5.1 Market Overview
- 11.5.2 Oral
- 11.5.3 Parenteral
- 11.5.4 Others
- 11.6 Exanthema Market by Distribution Channel
- 11.6.1 Market Overview
- 11.6.2 Hospital Pharmacy
- 11.6.3 Retail Pharmacy
- 11.7 Exanthema Market by Region
- 11.7.1 Market Overview
- 11.7.2 United States
- 11.7.3 EU-4 and the United Kingdom
- 11.7.3.1 Germany
- 11.7.3.2 France
- 11.7.3.3 Italy
- 11.7.3.4 Spain
- 11.7.3.5 United Kingdom
- 11.7.4 Japan
- 11.7.5 China
- 12 United States Exanthema Market
- 12.1 United States Exanthema Market Historical Value (2018-2024)
- 12.2 United States Exanthema Market Forecast Value (2025-2034)
- 12.3 United States Exanthema Market by Disease Type
- 12.3.1 Market Overview
- 12.3.2 Bacterial
- 12.3.3 Viral
- 12.3.4 Others
- 12.4 United States Exanthema Market by Therapy Type
- 12.4.1 Market Overview
- 12.4.2 Chemotherapy
- 12.4.3 Radiation Therapy
- 12.4.4 Targeted Therapy
- 13 EU-4 and United Kingdom Exanthema Market
- 13.1 EU-4 and United Kingdom Exanthema Market Historical Value (2018-2024)
- 13.2 EU-4 and United Kingdom Exanthema Market Forecast Value (2025-2034)
- 13.3 EU-4 and United Kingdom Exanthema Market by Disease Type
- 13.3.1 Market Overview
- 13.3.2 Bacterial
- 13.3.3 Viral
- 13.3.4 Others
- 13.4 EU-4 and United Kingdom Exanthema Market by Therapy Type
- 13.4.1 Market Overview
- 13.4.2 Chemotherapy
- 13.4.3 Radiation Therapy
- 13.4.4 Targeted Therapy
- 14 Japan Exanthema Market
- 14.1 Japan Exanthema Market Historical Value (2018-2024)
- 14.2 Japan Exanthema Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Exanthema Market by Disease Type
- 14.3.1 Market Overview
- 14.3.2 Bacterial
- 14.3.3 Viral
- 14.3.4 Others
- 14.4 EU-4 and United Kingdom Exanthema Market by Therapy Type
- 14.4.1 Market Overview
- 14.4.2 Chemotherapy
- 14.4.3 Radiation Therapy
- 14.4.4 Targeted Therapy
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Pfizer Inc
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 F. Hoffmann-La Roche Ltd
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Mylan N.V.
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Fresenius Kabi AG
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Hikma Pharmaceuticals PLC
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Teva Pharmaceutical Industries
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Bristol Myers Squibb Company
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Bayer AG
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 Sun Pharmaceutical Industries
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Manus Aktteva Biopharma LLP
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Perrigo Company plc
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Novartis AG
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 GSK Plc.
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 CIRON Drugs & Pharmaceuticals Pvt. Ltd.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Concord Laboratories
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Exanthema Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
